This JCI Insight study integrates bulk RNA-seq, scRNA-seq, spatial transcriptomics, IHC, and micro-CT to map human adrenal cortex development between 6–20 weeks post-conception, identifying (i) cortex zonation (definitive zone vs fetal zone), (ii) stage-dependent proliferation and steroidogenic capacity, (iii) a DZ boundary enriched in HOPX, and (iv) candidate mesenchyme–cortex signaling systems (e.g., RSPO3/LGR4, IGF2). The analysis is strong multimodality, but many “interaction” claims remain computationally inferred from ligand–receptor co-expression rather than causally tested.
Paper: An integrated single-cell analysis of human adrenal cortex development (JCI Insight, published July 24, 2023).
Core claim (high-level): the developing adrenal cortex undergoes rapid growth/vascularization; cortex is zonated into a definitive zone (DZ) and fetal zone (FZ); DZ shows higher cycling early; FZ is transcriptionally primed for androgen/DHEA synthesis; with time, DZ capacity to make cortisol and later aldosterone-like programs increases; and HOPX marks/defines a DZ boundary.
The scRNA-seq uses 4 developmental time points and reports the number of cells used for the UMAP at each stage.
Skeptical note: These are transcriptomic pathway inferences (enzyme machinery), not direct steroid metabolite measurements in the same cells/spots. The paper does acknowledge limitations in linking mRNA to physiology.
Major skeptical limitation: ligand–receptor inference from mRNA co-expression is not proof of protein secretion/engagement or functional necessity. The paper should be interpreted as generating priority candidates for follow-up, not as established causality.
Skeptical note: disease “presentation timing” is derived from published case reports assembled via literature search and reviewed; that is inherently susceptible to ascertainment/reporting bias. The paper acknowledges sample/access constraints as well.
Want targeted critiques from each author? Click the buttons for BGPT Author Reviews.
Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.